Share this Job

Assistant Technician I

Req ID:  41474

Tranent, ELN, GB, EH33 2NE

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Assistant Technician I

Job Summary

We are seeking an Assistant Technician I for our In Vitro Sciences Department site located in Elvingston Science Center, Gladsmuir (close to Edinburgh).


Your primary area of responsibility will be in all technical aspects of in vitro toxicology.  Typically, this is testing cells for toxicity in response to treatment.  You will be involved in routine cell culture, set up, conduct, analysis and data generation of the studies.  Full training will be given in all tasks and duties.


The following are minimum requirements related to the Assistant Technician I positions:

  • 5 Standard Grades including Maths, English and Biology
  • A positive and constructive approach to working in a busy laboratory environment and the ability to pay close attention to detail is essential.

A clean UK driving licence is beneficial as the role could involve transporting materials between the Elvingston site and Elphinstone Research Centre on a regular basis.


Salary banding for this position is £16,560 - £17,388.  Successful candidates will be appointed to the bottom of the pay band if they have no relevant experience.

In exceptional circumstances where the candidate has relevant equivalent experience, this will be taken into consideration.


All internal applicants should apply through the careers page on Talent Hub.


The closing date for this position is Thursday, 31 January 2019.


About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 13,000 employees within 80 facilities in 23 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 80% of the drugs approved by the FDA in 2017.


For more information, please visit